24 August 2018

Director/PDMR Dealing

The Company today announces that on 23 August 2018 Hilary Spence, Chief Financial Officer, purchased 220,000 Ordinary Shares at a purchase price of 4.50p.

Following these purchases, Hilary Spence holds 250,817 Ordinary Shares representing approximately 0.08 per cent of the Company's issued share capital.

The Company makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:

1 Details of the person discharging managerial responsibilities / person closely associated
a) Name Hilary Spence
2 Reason for the notification
a) Position/status Chief Financial Officer
b) Initial notification / Amendment Initial
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument

Identification code
Ordinary shares of 1p each

ISIN: GB00B94T6Y14
b) Nature of the transaction Purchase of Ordinary Shares
c) Price(s) and volume(s)
Price(s) Volume(s)
4.50p per share 220,000
d) Aggregated information
- Aggregated volume
- Price
N/A - single transaction
e) Date of the transaction 23 August 2018
f) Place of the transaction London Stock Exchange, XLON



Collagen Solutions Plc
Jamal Rushdy, CEO
Hilary Spence, CFO
Via Walbrook
Cenkos Securities plc (Nominated Adviser and Broker)
Steve Cox (Corporate Finance)
Stephen Keys
Tel: 0207 397 8900
Walbrook PR Ltd Tel: 020 7933 8780 or collagen@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
Helen Cresswell Mob: 07841 917 679